Ostrovnaya, Irina

Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers

Teo, M. Y., Seier, K., Ostrovnaya, I., Regazzi, A. M., Kania, B. E., Moran, M. M., Cipolla, C. K., Bluth, M. J., Chaim, J., Al-Ahmadie, H., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 544

A landscape of metabolic variation across tumor types

Reznik, E., Luna, A., Aksoy, B. A., Liu, E. M., La, K., Ostrovnaya, I., Creighton, C. J., Hakimi, A. A., & Sander, C. (2018) · Cell Systems

Cancer, Hypoxia, and MetabolismMetabolomics and Mass Spectrometry Studies

Cited by 172

Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer

Lenis, A. T., Ravichandran, V., Brown, S., Alam, S. M., Katims, A., Truong, H., Reisz, P. A., Vasselman, S., Nweji, B., Autio, K. A., et al. (2024) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersProstate Cancer Treatment and Research

Cited by 80

Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging

Pandit-Taskar, N., Zanzonico, P., Hilden, P., Ostrovnaya, I., Carrasquillo, J. A., & Modak, S. (2017) · Clinical Nuclear Medicine

Radiopharmaceutical Chemistry and ApplicationsAdvanced Radiotherapy Techniques

Cited by 22

A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma

Angeles, C. V., Velez, A., Rios, J., Laxa, B., Shum, D., Ruiz, P. D., Shen, Y., Ostrovnaya, I., Gularte-Mérida, R., Nacev, B. A., et al. (2022) · Clinical Cancer Research

Sarcoma Diagnosis and TreatmentChromatin Remodeling and Cancer

Cited by 13